AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05531513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Meditation
Description: The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~* Week 1 - Mindfulness of the Environment~* Week 2 - Embodied Mindfulness~* Week 3 - Embodied and Embedded Compassion~* Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9).
Study NCT05531513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Pamphlet
Description: The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9).
Study NCT05154565 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Guided meditation
Description: App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
Study NCT05154565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided meditation
Description: App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
Study NCT04541095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX_IMF
Description: Infant formula with large amounts of beta-palmitate (about 60%).
Study NCT04541095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ST_IMF
Description: Infant formula with low amounts beta-palmitate (about 10%).
Study NCT05900128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: workshop
Description: Patients will receive workshops and they will encourage to practice physical activity
Study NCT05900128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no workshop
Description: patients won't receive educative workshops
Study NCT06216223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment of anal diseases in inflammatory bowel patients
Description: treatment of anal diseases in inflammatory bowel patients
Study NCT06216223 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: treatment of anal diseases in inflammatory bowel patients
Description: treatment of anal diseases in inflammatory bowel patients
Study NCT06216223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: laser
Study NCT06216223 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: traditional surgery
Description: traditional surgery
Study NCT06355999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Color Feedback
Description: Feedback is given about the correctness of the response on the color dimension
Study NCT06355999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape Feedback
Description: Feedback is given about the correctness of the response on the shape dimension
Study NCT06082895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth self-efficacy enhancement training based on motivational interviewing method
Description: Birth self-efficacy enhancement training based on motivational interviewing method
Study NCT05564429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-SF12051
Description: Injected intravenously followed by PET scanning
Study NCT05458362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)
Description: Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention.
Study NCT05458362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group Anxiety Sensitivity Treatment
Description: Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
Study NCT01067651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster of Paris (POP) casting using the Ponseti Method
Study NCT01067651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semi-Rigid Fiberglass softcast using the Ponseti Method
Study NCT06118762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
Study NCT04949425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Patients will receive Adavosertib orally.
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT04922710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise
Description: Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
Study NCT05153863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C Scope Visualization System
Description: The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
Study NCT06229210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT06350006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904; Adebrelimab
Description: SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
Study NCT06350006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904; CAPOX; Adebrelimab
Description: SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
Study NCT04800094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Liver Fat Quantification Software
Description: All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
Study NCT04598841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement nutritional supporting
Description: Special medical formula for the purpose of formula food
Study NCT05376189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU
Description: An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
Study NCT05376189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5000 IU
Description: An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
Study NCT05376189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10000 IU
Description: An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
Study NCT05376189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Drug Combination
Description: Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
Study NCT05376189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Drug Combination
Description: Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06633328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells injection
Description: CD7 CAR T cells treat patients with severe aplastic anemia
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given Iv
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given Iv
Study NCT04628767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV
Study NCT04628767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given via injection
Study NCT04628767 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Given via injection
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04628767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given Iv
Study NCT04820036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Insulin Resistance
Description: Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
Study NCT04820036 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of Life Assessment
Description: Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
Study NCT04820036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Function Test
Description: EUS-guided liver biopsy and portal pressure gradient measurement
Study NCT04820036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Radiologic features of NASH
Description: Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
Study NCT04820036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serologic features of NASH
Description: Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
Study NCT04628767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine Sulfate
Description: Given Iv
Study NCT04929678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Braive™ Growth Modulation System (Braive™ GMS)
Description: The Braive™ GMS is designed as a growth-modulation, non-fusion technique, which utilizes patients' remaining growth potential to limit further progression of the curve, to provide correction of the thoracic spine, and allow continued growth while maintaining mobility.~The system consists of the following components: Braid, Fixed Angle Screws (FAS), Plate, and Break-Off Set Screw.
Study NCT06633328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with severe aplastic anemia
Study NCT05856032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella device
Description: Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
Study NCT05856032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Conventional chest physiotherapy techniques
Study NCT06633354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CAR T-cells
Description: Each subject receive CD5+ T-ALL Targeted CAR T-cells by intravenous infusion
Study NCT05191771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neovis Total Multi
Description: 1 drop in each eye, 4 times per day
Study NCT05191771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systane Balance
Description: 1 drop in each eye, 4 times per day
Study NCT06393829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applying the Early Mobilization Program
Description: A mobilization intervention based on the level of function (LOF) ( i.e. patients should be assessed for mobilization status within 24 hours of admission; mobilization should occur at least three times a day, and mobility should be progressive and scaled, tailored to the patient's abilities); The frequency of patient mobilization (primary outcome) will be assessed 20 weeks before implementation, during the 20 weeks of implementation and 20 weeks after the end of implementation (60 weeks in total).
Study NCT05011565 — intervention group
Intervention type: OTHER
Intervention: Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
Description: Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
Study NCT06632431 — intervention group
Intervention type: OTHER
Intervention: Endometrial cancer (EC)
Description: Endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) Histopathological slides for these cases will be reexamined and staged according to both the Federation of Gynecology and Obestetrics (FIGO) 2009 and updated Federation of Gynecology and Obestetrics (FIGO) 2023 endometrial staging systems. Upstaging refers to reclassification to a higher stage in the FIGO 2023 system compared to Federation of Gynecology and Obestetrics (FIGO)2009, while downstaging is the opposite.~All patients underwent lymph node dissection except those with Stage IA-Grades I and II endometrioid endometrial cancer and tumor size \<2 cm.
Study NCT06584422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression
Description: Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
Study NCT06584422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone friendly visits
Description: Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
Study NCT04707781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: chest CT
Description: assessment of interstitial lung disease using chest CT
Study NCT05297578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24-Valent Pneumococcal Conjugate Vaccine
Description: 0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
Study NCT05297578 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 20-valent Conjugate Vaccine
Description: 0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
Study NCT05903014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine
Description: we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
Study NCT05903014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
Study NCT05903014 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Enhancement Therapy
Description: Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
Study NCT04540406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBT-NM108
Description: Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
Study NCT04540406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Only
Description: Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.